This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. Over 600 subjects have been enrolled at 16 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Composite endpoint: Death or complications
Timeframe: Within 7 days of implant or hospital discharge, whichever is later
Device closure, defined as residual jet around the device ≤ 3mm
Timeframe: Assessed at first trans-esophageal echocardiogram (TEE) occurring between 30-240 days post-implant.
Composite endpoint: Ischemic stroke or systemic embolism
Timeframe: Through 24 months